VIR vs. BEAM, RLAY, FATE, ALLO, RVMD, EXEL, HALO, CRSP, KRYS, and IBRX
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), Fate Therapeutics (FATE), Allogene Therapeutics (ALLO), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology (NASDAQ:VIR) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.
Vir Biotechnology has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.
In the previous week, Vir Biotechnology had 11 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for Vir Biotechnology and 2 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.38 beat Vir Biotechnology's score of 0.55 indicating that Beam Therapeutics is being referred to more favorably in the news media.
Beam Therapeutics has a net margin of -37.33% compared to Vir Biotechnology's net margin of -677.69%. Beam Therapeutics' return on equity of -15.46% beat Vir Biotechnology's return on equity.
65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 15.6% of Vir Biotechnology shares are owned by company insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Vir Biotechnology presently has a consensus price target of $34.14, indicating a potential upside of 204.03%. Beam Therapeutics has a consensus price target of $40.18, indicating a potential upside of 73.12%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Beam Therapeutics.
Beam Therapeutics has higher revenue and earnings than Vir Biotechnology. Beam Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Vir Biotechnology received 1 more outperform votes than Beam Therapeutics when rated by MarketBeat users. However, 51.25% of users gave Beam Therapeutics an outperform vote while only 49.41% of users gave Vir Biotechnology an outperform vote.
Summary
Beam Therapeutics beats Vir Biotechnology on 11 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
